EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte StudieVergleichsstudie

Are Two Gliflozins Different: A Prospective Multicenter Randomized Study to Assess Effect of Remogliflozin Compared With Empagliflozin on Biomarkers of Heart Failure in Indian Patients With Type 2 Diabetes Mellitus with Chronic Heart Failure (REMIT-HF Study)

Shantanu Sengupta, Jayagopal Pathiyilbalagopalan, Ashwani Mehta, J P S Sawhney, Satish Suryavanshi, Naveen Jamwal, Dilip Kadam, Ambanna Gowda, Ramesh Dargad, Amit Bhate, Vinod Kapoor, Sumit Bhushan und 4 weitere

Journal of Cardiac Failure · 2025

DOI: 10.1016/j.cardfail.2024.07.020 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Cardiac Failure, 2025. Verfasst von Shantanu Sengupta und 15 weiteren Autor:innen. Beteiligte Einrichtung: Sengupta Hospital and Research Institute, Nagpur, India. Electronic address: senguptasp@gmail.com. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucosides, Heart Failure, Benzhydryl Compounds. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 9 Literaturangaben. Gefördert von: Glenmark Pharmaceuticals Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

There is limited data comparing two gliflozins on their effect on biomarkers in diabetic patients with chronic heart failure. A prospective, multicenter, active controlled, double-arm, investigator-initiated, interventional study enrolled 250 adults with type 2 diabetes mellitus (T2DM) and comorbid congestive heart failure (CHF; left ventricular ejection fraction [LVEF] 600 pg/mL). A total of 125 patients were allocated each to a remogliflozin (R) and empagliflozin (E) group and followed up for 24 weeks. The primary endpoint was the mean percentage change from baseline in NT-proBNP level after 24 weeks. There was significant improvement from baseline in mean NT-proBNP level in both groups after 24 weeks. However, there was no significant difference between the two groups (P = .214). The mean NT-proBNP level improved from 2078.15 ± 1764.70 pg/mL at baseline to 1185.06 ± 1164.21 pg/mL at 6 months in the R-group (P ≤ .001) and from 2283.98 ± 1759.15 pg/mL at baseline to 1395.33 ± 1304.18 pg/mL at 6 months in the E-group (P < .001). LVEF and LV volumes improved in both groups. The glycemic parameters (HbA1c, FPG, and PPG) demonstrated a significant reduction from baseline to week 24 in both groups. Similar improvement was seen in heart rate, blood pressure, and weight reduction over 6 months in both groups. There was no drug-related serious adverse events in any group. Remogliflozin and empagliflozin significantly improve glycemic parameters and NT-proBNP levels as the index of the therapeutic effects in T2DM patients with CHF. The positive effects are comparable in both groups.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2GlucosidesHeart FailureBenzhydryl CompoundsSodium-Glucose Transporter 2 InhibitorsHumansMaleFemaleMiddle AgedProspective StudiesBiomarkersAgedNatriuretic Peptide, BrainIndiaPeptide FragmentsChronic DiseaseTreatment OutcomeFollow-Up StudiesDouble-Blind Method

Substanzen

GlucosidesBenzhydryl CompoundsBiomarkersempagliflozinSodium-Glucose Transporter 2 InhibitorsNatriuretic Peptide, BrainPeptide Fragmentspro-brain natriuretic peptide (1-76)

Autor:innen und Institutionen

  • Sengupta Hospital and Research Institute, Nagpur, India. Electronic address: senguptasp@gmail.com.
  • Lakshmi Hospital, Palakkad, India.
  • Sir Gangaram Hospital, Delhi, India.
  • SMC Heart Institute, Raipur, India.
  • RML Institute, Lucknow, India.
  • Care Hospital, Pune, India.

Förderung

  • Glenmark Pharmaceuticals Ltd

Zitieren

APA

Sengupta, S., Pathiyilbalagopalan, J., Mehta, A., Sawhney, J. P. S., Suryavanshi, S., Jamwal, N., Kadam, D., Gowda, A., Dargad, R., Bhate, A., Kapoor, V., Bhushan, S., Mane, A., Gadkari, R., Patil, S., & Barkate, H. (2025). Are Two Gliflozins Different: A Prospective Multicenter Randomized Study to Assess Effect of Remogliflozin Compared With Empagliflozin on Biomarkers of Heart Failure in Indian Patients With Type 2 Diabetes Mellitus with Chronic Heart Failure (REMIT-HF Study). Journal of Cardiac Failure. https://doi.org/10.1016/j.cardfail.2024.07.020

Vancouver

Sengupta S, Pathiyilbalagopalan J, Mehta A, Sawhney JPS, Suryavanshi S, Jamwal N, et al. Are Two Gliflozins Different: A Prospective Multicenter Randomized Study to Assess Effect of Remogliflozin Compared With Empagliflozin on Biomarkers of Heart Failure in Indian Patients With Type 2 Diabetes Mellitus with Chronic Heart Failure (REMIT-HF Study). Journal of Cardiac Failure. 2025. doi:10.1016/j.cardfail.2024.07.020

BibTeX
@article{Sengupta2025,
  author = {Sengupta, Shantanu and Pathiyilbalagopalan, Jayagopal and Mehta, Ashwani and Sawhney, J P S and Suryavanshi, Satish and Jamwal, Naveen and Kadam, Dilip and Gowda, Ambanna and Dargad, Ramesh and Bhate, Amit and Kapoor, Vinod and Bhushan, Sumit and Mane, Abhishek and Gadkari, Rujuta and Patil, Saiprasad and Barkate, Hanmant},
  title = {Are Two Gliflozins Different: A Prospective Multicenter Randomized Study to Assess Effect of Remogliflozin Compared With Empagliflozin on Biomarkers of Heart Failure in Indian Patients With Type 2 Diabetes Mellitus with Chronic Heart Failure (REMIT-HF Study)},
  journal = {Journal of Cardiac Failure},
  year = {2025},
  doi = {10.1016/j.cardfail.2024.07.020}
}
Kostenlos starten →